AbbVie (ABBV) reports positive phase 1 multiple ascending dose results for ABBV-295, a long-acting amylin analog

AbbVie's positive phase 1 results for ABBV-295 indicate strong potential for its long-acting amylin analog, suggesting a promising addition to their pipeline, particularly in the diabetes space.

Newsquawk StaffPublished On the live feed at 5 more headlines followed before this page went public
Newsquawk headlinesUTC

Israeli PM Netanyahu's adviser, speaking to CBS, says the position of the Supreme Leader carries risks and we made it clear that senior positions in Iran are vulnerable to being targeted

Novo Nordisk (NOVOB DC) confirms will sell WeGovy and Ozempic on Hims & Hers (HIMS) platform

AbbVie (ABBV) reports positive phase 1 multiple ascending dose results for ABBV-295, a long-acting amylin analog

India's government officials confirm they will not release strategic crude oil stockpiles

US President Trump will not go to any cities beyond Beijing during his visit to China scheduled for late this month because of his tight schedule and security concerns, SCMP sources report

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This could positively impact investor sentiment and drive stock performance, especially as the market evaluates future revenue contributions from new therapies in their portfolio.

Related headlines

The whole workspace, free to try.

Try it free